14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
UFPT vs HAE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
HAE Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)
HAE Overall Winner
6-Pillar Tally: UFPT 1 – 4 HAE (1 Tie)
Matrix Metrics: UFPT 4 – 6 HAE
As of Nov 16, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas HAE carries 51.4/100 (HOLD) at $121.34 (22.9x Forward P/E, 18.8% operating margin).
Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UFPT vs HAE. Trailing 12-month operating profitability (UFPT 15.4% vs HAE 18.8%) and valuation multiples (UFPT 24.7x vs HAE 22.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment13.5% of Rev ($88M)
90D Engineering Disclosures0 Published
HAE Moat ProfileScale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $5.6B market capitalization and 18.8% operating margin.
OpEx & R&D Reinvestment41.0% of Rev ($567M)
90D Engineering Disclosures0 Published
Investor FAQ UFPT vs HAE Key Questions & Quantitative Answers
As of Nov 16, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas HAE carries 51.4/100 (HOLD) at $121.34 (22.9x Forward P/E, 18.8% operating margin). Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
UFPT leads the Growth & Scale pillar: UFPT posts +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin), compared with HAE at +9.3% YoY revenue growth and +23.5% YoY earnings growth on $1.38B TTM revenue (59.8% gross margin, 18.8% operating margin). On trailing 12-month operating scale, UFPT generates $650M in USD-normalized revenue versus $1.38B for HAE. In operating R&D and SG&A reinvestment, UFPT deploys 13.5% of Rev ($88M) (0 90-day corporate R&D disclosures) versus 41.0% of Rev ($567M) (0 disclosures) for HAE.
HAE screens cheaper on headline valuation multiples. UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin), whereas HAE trades at 22.9x Forward P/E, 54.4x Trailing P/E, 1.92x PEG, and 4.0x EV/Revenue (26.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UFPT (17.2% ROE) versus HAE (11.9% ROE) capital efficiency.
In options market volatility and institutional positioning, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk). By comparison, HAE carries 32.7% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.